Search All Patents in Cannabis: Medical
Patent US10849860
Issued 2020-12-01
Use Of Cannabinoids In The Treatment Of Epilepsy
The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
Much More than Average Length Specification
View the Patent Matrix® Diagram to Explore the Claim Relationships
USPTO Full Text Publication >
- 1. A method of treating drop seizures in a patient with Lennox-Gastaut syndrome or Dravet syndrome, comprising administering to the patient cannabidiol (CBD), wherein the CBD has a purity of at least 95% (w/w), and the CBD is administered at a dose of 5 mg/kg/day, and then the dose is increased by 2 to 5 mg/kg increments, up to 25 mg/kg/day.
- 20. A method of treating drop seizures in a patient with Lennox-Gastaut syndrome or Dravet syndrome, comprising administering to the patient cannabidiol (CBD), wherein the CBD has a purity of at least 95% (w/w), and wherein the CBD is administered at a dose ranging from 5 mg/kg/day to 20 mg/kg/day.
